Patient ID
|
Overall survival (months)
|
Pre-DC Vax CD3+CD8+ EC-50
|
Post-DC Vax CD3+CD8+ EC-50
|
Pre-DC Vax CD3+CD4+ EC50
|
Post-DC Vax CD3+CD4+ EC-50
|
---|
1-708
|
33.83
|
128.2
|
13.16
|
3.528
|
13.39
|
34-730
|
16.23
|
126.2
|
66.01
|
20.73
|
0.005
|
36-852
|
>43.9
|
27.95
|
0.017
|
4.407
|
0.002
|
6-815
|
17.3
|
1.854
|
0.196
|
0.002
|
2.355
|
19-539
|
34.9
|
8.223
|
14.27
|
1.386
|
1.178
|
GAA-03
|
35.3
|
60.52
|
18.63
|
29.64
|
0.003
|
GAA-05
|
11.73
|
38.2
|
34.69
|
11.43
|
5.245
|
GAA-07
|
17.2
|
16.52
|
6.07
|
5.446
|
5.237
|
GAA-09
|
11.0
|
31.19
|
22.38
|
7.2
|
7.7
|
AVERAGE:
| |
50.70
|
19.15
|
9.31
|
3.90
|
SEM:
| |
16.90
|
6.38
|
3.10
|
1.30
|
T-test:
| |
0.045
| |
0.223
| |
-
1The EC-50 for IL-2 responsiveness (pSTAT-5) was calculated in CD3+8+ and CD3+CD4+ peripheral blood T cells after a 20-minute stimulation with increasing dosages of IL-2, FACS analysis, and log transformation.